Kaleido Biosciences Inc reports results for the quarter ended in September - Earnings Summary

Kaleido Biosciences

01/11/2021 13:32

* Kaleido Biosciences Inc  KLDO.OQ  reported a quarterly
adjusted loss of 54 cents​​ per share for the quarter ended in
September. The mean expectation of six analysts for the quarter
was for a loss of 54 cents per share.
* Revenue fell 78.4% to $104.00 thousand from a year ago; 
analysts expected $170.00 thousand. 
* Kaleido Biosciences Inc's reported EPS for the quarter was a
loss of 54 cents​.
* The mean earnings estimate of analysts had risen by about 7.1%
in the last three months.​ 
* In the last 30 days there have been no negative revisions of
earnings estimates 
* Kaleido Biosciences Inc shares had fallen by 21.2% this
quarter and lost 52.7% so far this year.
* The company reported a quarterly loss of $23.09 million.
* Wall Street's median 12-month price target for Kaleido
Biosciences Inc is $19.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and 2 "sell" or "strong sell." 
This summary was machine generated November 1 at 01:32 p.m.
 ​All figures in US dollars unless otherwise stated